dub
1983
- The Company was incorporated as a partnership firm by by Dilip Sanghvi and his family as a partnership firm.
The company was to manufacture pharmaceutical formulation at Vapi,
Gujarat. It was created as a public Ltd. Company effective from Ist
March. The promoter was also Dilip Sanghvi. The Company has specialization in
in selected therapeutic segment related to neurology, cardiology, psychiatry,
and gastroenterology.
1994
- The Bulk drug plant was commissioned at Panoli. In April, the second
formulation plant at Silvana was commissioned.
- During October, the company undertook to increase bulk drugs production
capacity at Panoli from 62,000 Kgs. p.a. to 92000 Kgs.
p.a. Also formulation unit was to be increased from 570 million tablets p.a.
to 1800 millions pa.
- The Company gave the proposal to to modernise Vapi formulation unit and
enhance its capacity from 480 million tablets to 1440 million
tablets p.a. It was also suggested to set up additional facilities at
the R&D centre SPARC.
- 71,85,000 No. of equity shares issued to promoters etc. were issued to promoters.
1995
- In the synergy division a couple of more products viz. Syndopa CR and `Clofranil SR
were introduced.
- The Company was incorporated as a partnership firm by by Dilip Sanghvi and his family as a partnership firm.
The company was to manufacture pharmaceutical formulation at Vapi,
Gujarat. It was created as a public Ltd. Company effective from Ist
March. The promoter was also Dilip Sanghvi. The Company has specialization in
in selected therapeutic segment related to neurology, cardiology, psychiatry,
and gastroenterology.
1994
- The Bulk drug plant was commissioned at Panoli. In April, the second
formulation plant at Silvana was commissioned.
- During October, the company undertook to increase bulk drugs production
capacity at Panoli from 62,000 Kgs. p.a. to 92000 Kgs.
p.a. Also formulation unit was to be increased from 570 million tablets p.a.
to 1800 millions pa.
- The Company gave the proposal to to modernise Vapi formulation unit and
enhance its capacity from 480 million tablets to 1440 million
tablets p.a. It was also suggested to set up additional facilities at
the R&D centre SPARC.
- 71,85,000 No. of equity shares issued to promoters etc. were issued to promoters.
1995
- In the synergy division a couple of more products viz. Syndopa CR and `Clofranil SR
were introduced.
Comments
Post a Comment